Online inquiry

IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5485MR)

This product GTTS-WQ5485MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL6 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000600.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569
UniProt ID P05231
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5485MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2236MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA aVWF81
GTTS-WQ3784MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ507MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 47H4
GTTS-WQ11523MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ15201MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TA-650
GTTS-WQ5524MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDP4940
GTTS-WQ7193MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ3919MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BCD-135
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW